Glaukos Corp
NYSE:GKOS
Intrinsic Value
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. [ Read More ]
The intrinsic value of one GKOS stock under the Base Case scenario is hidden USD. Compared to the current market price of 112.72 USD, Glaukos Corp is hidden .
Valuation Backtest
Glaukos Corp
Run backtest to discover the historical profit from buying and selling GKOS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Balance Sheet Decomposition
Glaukos Corp
Current Assets | 388.6m |
Cash & Short-Term Investments | 272.9m |
Receivables | 46.5m |
Other Current Assets | 69.2m |
Non-Current Assets | 544.7m |
PP&E | 172.1m |
Intangibles | 348.1m |
Other Non-Current Assets | 24.6m |
Current Liabilities | 72.2m |
Accounts Payable | 12.8m |
Accrued Liabilities | 59.5m |
Non-Current Liabilities | 410.4m |
Long-Term Debt | 353.4m |
Other Non-Current Liabilities | 57m |
Earnings Waterfall
Glaukos Corp
Revenue
|
326.4m
USD
|
Cost of Revenue
|
-77.8m
USD
|
Gross Profit
|
248.7m
USD
|
Operating Expenses
|
-369.7m
USD
|
Operating Income
|
-121m
USD
|
Other Expenses
|
-19.8m
USD
|
Net Income
|
-140.9m
USD
|
Free Cash Flow Analysis
Glaukos Corp
USD | |
Free Cash Flow | USD |
GKOS Profitability Score
Profitability Due Diligence
Glaukos Corp's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Glaukos Corp's profitability score is hidden . The higher the profitability score, the more profitable the company is.
GKOS Solvency Score
Solvency Due Diligence
Glaukos Corp's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Glaukos Corp's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GKOS Price Targets Summary
Glaukos Corp
According to Wall Street analysts, the average 1-year price target for GKOS is 115.91 USD with a low forecast of 101 USD and a high forecast of 136.5 USD.
Ownership
GKOS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GKOS Price
Glaukos Corp
Average Annual Return | -6.29% |
Standard Deviation of Annual Returns | 26.06% |
Max Drawdown | -70% |
Market Capitalization | 5.6B USD |
Shares Outstanding | 50 367 500 |
Percentage of Shares Shorted | 11.86% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company is headquartered in San Clemente, California and currently employs 727 full-time employees. The company went IPO on 2015-06-25. The company is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants that are designed to elute pharmaceuticals.
Contact
IPO
Employees
Officers
The intrinsic value of one GKOS stock under the Base Case scenario is hidden USD.
Compared to the current market price of 112.72 USD, Glaukos Corp is hidden .